From November 11 to 13, 2026, the 95th China International Trade Fair for Pharmaceutical APIs, Intermediates, Packaging and Equipment (API China) opened at the Wuhan International Expo Center. Five years on, this major pharmaceutical industry gathering returned to Wuhan, bringing together more than 1,200 leading companies from upstream and downstream segments and covering the full industry chain of APIs, intermediates, excipients, packaging materials and pharmaceutical equipment. Sichuan Xieli Pharmaceutical Co., Ltd. attended once again. Under the theme “Natural Origins, Shared Globally,” We presented our natural-origin specialty APIs and CDMO capabilities at Booth B4H25, and explored new opportunities with long-standing and prospective customers from China and abroad.
At the Booth: Star Products Gathered, Certified Strength Displayed
At this edition, Xieli Pharma maintained its core product portfolio of flavonoids, bile acids, alkaloids and oncology APIs, with core products on display including Diosmin, Hesperidin, Rutin, Troxerutin, Ursodeoxycholic acid and Cytisine, together with specialty intermediates and customized CDMO solutions. The booth also displayed the company’s EU CEP, US FDA qualification and Japanese GMP certification, reflecting a quality management system that spans the entire chain from R&D through manufacturing to supply.
In-Depth Dialogue: Connecting Global Demand, Consolidating Partnerships
Throughout the three-day exhibition, Xieli’s domestic sales, international trade team and R&D staff were on site for the full duration. They met with long-standing strategic partners to review cooperation details on capacity and supply and on process improvements, and engaged with customers in emerging markets to exchange views on expanding the use of natural products in cardiovascular, cerebrovascular and digestive applications. Visitor traffic at the booth remained steady, and buyers and technical experts from China and abroad held several rounds of practical discussions.
Looking Ahead: Built on Nature, Guided by Compliance
Global demand for natural-origin, high-barrier specialty APIs continues to rise steadily. Xieli Pharma remains grounded in its core natural-origin technologies and, drawing on its Pengzhou manufacturing site and its international certification framework, continues to broaden a diversified portfolio that ranges from natural active ingredients to specialty fully synthetic APIs. API China in Wuhan marked another practical step in the company’s work to deepen its global supply chain footprint. Going forward, Xieli Pharma will continue to use API China and other international exhibitions to translate its plant-derived, high-barrier specialty APIs into more stable and more compliant supply capability, working with global partners to advance human health.









